- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Drug Costs and Benefit Design
Genevieve Kumapley, PharmD, BCOP, reflects on the significant out-of-pocket (OOP) costs associated with oral oncolytics and suggests how a change in benefit design can help patients afford the treatments they need.
“[Under the prescription benefit,] patients are required to now cover anywhere from 25% to 30% of costs, notes Dr Kumapley. “That’s significant.”
High costs burden patients and affect their adherence to treatment, remarks Dr Kumapley. For instance, patients prescribed high-cost drugs are less likely to fill their prescriptions, and although patient assistance programs are available to assist patients with the costs of treatment, drug benefit design should be reevaluated.
Dr Kumapley explains that currently, while intravenous therapies are covered under the medical benefit, oral oncolytics are covered under the prescription benefit. There is a large disparity in patient OOP cost, with the patient responsible for a higher cost under the prescription benefit. In oncology, she adds, coverage of oral oncolytics under the medical benefit may be more beneficial in terms of reduced patient OOP cost.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
